Skip to content
In deliveryUnited KingdomGoodsFramework agreement£85,785,000

NHS National Framework Agreement for Omalizumab

Published
Published 26 August 2025
Deadline
Closed 30 October 2025

Overview

Project title: NHS National Framework for Omalizumab commencing 1st February 2026 Offer reference number: CM/TNS/25/5734 Period of framework: 1 February 2026 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Key details

Country
United Kingdom
Status
In delivery
Category
Goods
Estimated value
£85,785,000
Procedure
Open
Contract type
Framework agreement
SME suitable
Yes
Published
26 August 2025
Questions by
23 October 2025
Deadline
Closed
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
£174,866,000
Award date
26 November 2025
Contract period
1 February 2026 → 31 August 2027
Winners
  • CELLTRION HEALTHCARE UNITED KINGDOM LIMITED
  • Celltrion Healthcare United Kingdom Limited
  • MERCURY PHARMACEUTICALS LIMITED
  • NOVARTIS PHARMACEUTICALS UK LIMITED

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract

    30 December 2025

    View notice ↗
  2. Contract

    28 November 2025

    View notice ↗
  3. Contract Notice

    3 October 2025

    View notice ↗
  4. Prior Information Notice

    26 August 2025

    View notice ↗

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: NHS National Framework Agreement for Omalizumab — won by CELLTRION HEALTHCARE UNITED KINGDOM LIMITED +3 — Skim